Company intelligence / Profile preview

InnoCIMAb

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

InnoCIMAb is a Singapore-based biotechnology joint venture established between the Center of Molecular Immunology (CIM) in Cuba and Inno-Gene Holdings. The company focuses on the development, manufacturing, and commercialization of therapeutic monoclonal antibodies for the treatment of cancer and other chronic diseases. Its lead product is Nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is approved in multiple territories for various oncology indications. InnoCIMAb serves as a strategic hub for clinical development and market expansion of CIM's portfolio in the Asia-Pacific region and beyond.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Center of Molecular Immunology (CIM)Inno-Gene HoldingsBioconDaiichi Sankyo

Beyond the preview

Go deeper on InnoCIMAb.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoCIMAb.

Explore the full profile